EPIPROBE Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $15.7M

  • Investors
  • 2

EPIPROBE General Information

Description

Developer of molecular diagnosis approaches designed for early cancer screening. The company specializes in the research on DNA methylation that can be widely applied in early tumor screening, auxiliary diagnosis, efficacy evaluation, and recurrence monitoring, enabling the real-time monitoring of tumor occurrence and development.

Contact Information

Website
www.epiprobe.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 701, Building 6, Phase II of Juke Biological Park
  • No. 333 Guiping Road, Xuhui District
  • Shanghai
  • China
+86 021
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Room 701, Building 6, Phase II of Juke Biological Park
  • No. 333 Guiping Road, Xuhui District
  • Shanghai
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EPIPROBE Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 11-Apr-2022 $15.7M Completed Generating Revenue
1. Early Stage VC 01-Aug-2020 Completed Generating Revenue
To view EPIPROBE’s complete valuation and funding history, request access »

EPIPROBE Patents

  • 70

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 41

    Pending

  • Expiring in next 12 mo

EPIPROBE Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026057082-A1 Method for preparing bisulfite dna and use thereof Pending 14-Sep-2024
WO-2025223353-A1 Dna methylation markers tagme-11, 12, and 13 suitable for tumor identification and use thereof Pending 23-Apr-2024
WO-2025223358-A1 Dna methylation markers tagme-14, 15, and 16 and use thereof in tumor analysis Pending 23-Apr-2024
WO-2025223355-A1 Dna methylation markers tagme-8, 9, and 10 for broad-spectrum identification of cancer and use thereof Pending 23-Apr-2024
WO-2025073215-A1 Dna methylation marker tagme-4 and use thereof in tumor detection Inactive 05-Oct-2023 C12Q1/6886
To view EPIPROBE’s complete patent history, request access »

EPIPROBE Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tianjin Yiyi Hygiene Products Corporation Minority
Chobe Capital Venture Capital Minority
To view EPIPROBE’s complete investors history, request access »

Ready to get started?

Request a free trial

EPIPROBE FAQs

  • When was EPIPROBE founded?

    EPIPROBE was founded in 2018.

  • Where is EPIPROBE headquartered?

    EPIPROBE is headquartered in Shanghai, China.

  • What industry is EPIPROBE in?

    EPIPROBE’s primary industry is Discovery Tools (Healthcare).

  • Is EPIPROBE a private or public company?

    EPIPROBE is a Private company.

  • What is EPIPROBE’s current revenue?

    The current revenue for EPIPROBE is .

  • How much funding has EPIPROBE raised over time?

    EPIPROBE has raised $15.7M.

  • Who are EPIPROBE’s investors?

    Tianjin Yiyi Hygiene Products and Chobe Capital have invested in EPIPROBE.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process